Effect of dexamethasone on insulin secretion

Examination of underlying mechanisms

Ajay Sood, Faramarz Ismail-Beigi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To study the mechanism of increased insulin secretion in response to short-term administration of dexamethasone. Methods: Male Wistar rats were injected intraperitoneally with dexamethasone (dexamethasone; 200 mcg/kg body weight per day) or saline for 3 consecutive days. Insulin secretion in response to glucose, ionomycin, and KCl was quantified in islets isolated from the animals, and the amount of glucokinase was measured by Western blot. Results: Dexamethasone-treated animals had 1.18-fold higher fasting blood glucose concentration and 6.5-fold increase in fasting serum insulin concentration compared with findings from animals injected with saline. Compared with islets isolated from control rats, islets from dexamethasone-treated rats secreted more insulin at 60 minutes in response to 5.5 mM glucose (416.4 vs 115.6 fmoles/10 islets, P = .011) and in response to 16.6 mM glucose (985.5 vs 520.6 fmoles/10 islets, P = .014); no change in insulin secretion was observed at 10 minutes. Insulin secretion from islets of dexamethasone-treated rats and control rats was not differentially augmented in response to either ionomycin or potassium chloride. Glucokinase expression was not altered by treatment with dexamethasone. Conclusions: Augmentation of insulin secretion in response to glucose in the pancreatic islets from dexamethasone-treated rats is preserved in islets studied in vitro. The increase in glucose-stimulated insulin secretion appears to be mediated by steps upstream to β-cell membrane depolarization and the attended increase in intracellular calcium in the signaling pathway of insulin secretion.

Original languageEnglish (US)
Pages (from-to)763-769
Number of pages7
JournalEndocrine Practice
Volume16
Issue number5
DOIs
StatePublished - Sep 1 2010
Externally publishedYes

Fingerprint

Dexamethasone
Insulin
Glucose
Glucokinase
Ionomycin
Fasting
Calcium Signaling
Potassium Chloride
Secretory Pathway
Islets of Langerhans
Blood Glucose
Wistar Rats
Western Blotting
Body Weight
Cell Membrane
Serum

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of dexamethasone on insulin secretion : Examination of underlying mechanisms. / Sood, Ajay; Ismail-Beigi, Faramarz.

In: Endocrine Practice, Vol. 16, No. 5, 01.09.2010, p. 763-769.

Research output: Contribution to journalArticle

@article{298abef5744f415a9bfa98013bd91fc5,
title = "Effect of dexamethasone on insulin secretion: Examination of underlying mechanisms",
abstract = "Objective: To study the mechanism of increased insulin secretion in response to short-term administration of dexamethasone. Methods: Male Wistar rats were injected intraperitoneally with dexamethasone (dexamethasone; 200 mcg/kg body weight per day) or saline for 3 consecutive days. Insulin secretion in response to glucose, ionomycin, and KCl was quantified in islets isolated from the animals, and the amount of glucokinase was measured by Western blot. Results: Dexamethasone-treated animals had 1.18-fold higher fasting blood glucose concentration and 6.5-fold increase in fasting serum insulin concentration compared with findings from animals injected with saline. Compared with islets isolated from control rats, islets from dexamethasone-treated rats secreted more insulin at 60 minutes in response to 5.5 mM glucose (416.4 vs 115.6 fmoles/10 islets, P = .011) and in response to 16.6 mM glucose (985.5 vs 520.6 fmoles/10 islets, P = .014); no change in insulin secretion was observed at 10 minutes. Insulin secretion from islets of dexamethasone-treated rats and control rats was not differentially augmented in response to either ionomycin or potassium chloride. Glucokinase expression was not altered by treatment with dexamethasone. Conclusions: Augmentation of insulin secretion in response to glucose in the pancreatic islets from dexamethasone-treated rats is preserved in islets studied in vitro. The increase in glucose-stimulated insulin secretion appears to be mediated by steps upstream to β-cell membrane depolarization and the attended increase in intracellular calcium in the signaling pathway of insulin secretion.",
author = "Ajay Sood and Faramarz Ismail-Beigi",
year = "2010",
month = "9",
day = "1",
doi = "10.4158/EP09372.OR",
language = "English (US)",
volume = "16",
pages = "763--769",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "5",

}

TY - JOUR

T1 - Effect of dexamethasone on insulin secretion

T2 - Examination of underlying mechanisms

AU - Sood, Ajay

AU - Ismail-Beigi, Faramarz

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Objective: To study the mechanism of increased insulin secretion in response to short-term administration of dexamethasone. Methods: Male Wistar rats were injected intraperitoneally with dexamethasone (dexamethasone; 200 mcg/kg body weight per day) or saline for 3 consecutive days. Insulin secretion in response to glucose, ionomycin, and KCl was quantified in islets isolated from the animals, and the amount of glucokinase was measured by Western blot. Results: Dexamethasone-treated animals had 1.18-fold higher fasting blood glucose concentration and 6.5-fold increase in fasting serum insulin concentration compared with findings from animals injected with saline. Compared with islets isolated from control rats, islets from dexamethasone-treated rats secreted more insulin at 60 minutes in response to 5.5 mM glucose (416.4 vs 115.6 fmoles/10 islets, P = .011) and in response to 16.6 mM glucose (985.5 vs 520.6 fmoles/10 islets, P = .014); no change in insulin secretion was observed at 10 minutes. Insulin secretion from islets of dexamethasone-treated rats and control rats was not differentially augmented in response to either ionomycin or potassium chloride. Glucokinase expression was not altered by treatment with dexamethasone. Conclusions: Augmentation of insulin secretion in response to glucose in the pancreatic islets from dexamethasone-treated rats is preserved in islets studied in vitro. The increase in glucose-stimulated insulin secretion appears to be mediated by steps upstream to β-cell membrane depolarization and the attended increase in intracellular calcium in the signaling pathway of insulin secretion.

AB - Objective: To study the mechanism of increased insulin secretion in response to short-term administration of dexamethasone. Methods: Male Wistar rats were injected intraperitoneally with dexamethasone (dexamethasone; 200 mcg/kg body weight per day) or saline for 3 consecutive days. Insulin secretion in response to glucose, ionomycin, and KCl was quantified in islets isolated from the animals, and the amount of glucokinase was measured by Western blot. Results: Dexamethasone-treated animals had 1.18-fold higher fasting blood glucose concentration and 6.5-fold increase in fasting serum insulin concentration compared with findings from animals injected with saline. Compared with islets isolated from control rats, islets from dexamethasone-treated rats secreted more insulin at 60 minutes in response to 5.5 mM glucose (416.4 vs 115.6 fmoles/10 islets, P = .011) and in response to 16.6 mM glucose (985.5 vs 520.6 fmoles/10 islets, P = .014); no change in insulin secretion was observed at 10 minutes. Insulin secretion from islets of dexamethasone-treated rats and control rats was not differentially augmented in response to either ionomycin or potassium chloride. Glucokinase expression was not altered by treatment with dexamethasone. Conclusions: Augmentation of insulin secretion in response to glucose in the pancreatic islets from dexamethasone-treated rats is preserved in islets studied in vitro. The increase in glucose-stimulated insulin secretion appears to be mediated by steps upstream to β-cell membrane depolarization and the attended increase in intracellular calcium in the signaling pathway of insulin secretion.

UR - http://www.scopus.com/inward/record.url?scp=78149346446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149346446&partnerID=8YFLogxK

U2 - 10.4158/EP09372.OR

DO - 10.4158/EP09372.OR

M3 - Article

VL - 16

SP - 763

EP - 769

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 5

ER -